background
dengu
viru
denv
still
pose
global
public
health
threat
vaccin
antivir
therapi
current
avail
antibodi
play
distinct
role
control
denv
infect
neutral
antibodi
protect
denv
infect
wherea
subneutr
concentr
antibodi
increas
denv
infect
term
antibodydepend
enhanc
ade
plaquebas
assay
repres
wide
accept
method
measur
neutral
enhanc
antibodi
result
studi
novel
report
virusbas
system
develop
measur
neutral
ade
activ
stabl
renilla
luciferas
report
denv
lucdenv
produc
robust
luciferas
signal
cell
use
establish
assay
valid
tradit
plaquebas
assay
luciferas
valu
analysi
use
variou
known
denvspecif
monoclon
antibodi
show
good
repeat
well
linear
correl
convent
plaquebas
assay
newli
develop
assay
final
valid
clinic
sampl
infect
anim
individu
conclus
report
virusbas
assay
neutral
enhanc
antibodi
evalu
rapid
lower
cost
high
throughput
help
laboratori
detect
epidemiolog
investig
denv
antibodi
four
serotyp
dengu
viru
denv
belong
genu
flaviviru
within
famili
flavivirida
clinic
manifest
denv
infect
cover
wide
rang
symptom
mild
dengu
fever
df
sever
life
threaten
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
commonli
dhfdss
associ
sequenti
denv
infect
differ
serotyp
annual
million
peopl
countri
infect
denv
dhfdss
fatal
affect
individu
vaccin
specif
antivir
drug
current
avail
denv
typic
positivesens
singlestrand
rna
viru
genom
kb
length
encod
three
structur
protein
c
prm
e
seven
nonstructur
protein
neutral
antibodi
predominantli
induc
e
protein
laboratori
clinic
studi
demonstr
protect
anim
individu
denv
infect
best
correl
titer
neutral
antibodi
howev
preexist
subneutr
concentr
antibodi
nonneutr
antibodi
also
evidenc
enhanc
denv
infect
fc
gamma
receptor
posit
cell
appear
risk
factor
sever
diseas
phenomenon
known
antibodydepend
enhanc
ade
infect
thu
human
antibodi
believ
play
distinct
role
control
denv
infect
import
character
antibodi
neutral
enhanc
activ
denv
basic
appli
research
current
plaquebas
analysi
wide
accept
method
measur
neutral
enhanc
antibodi
recommend
world
health
organ
howev
tradit
method
timeconsum
labor
intens
suitabl
largescal
sampl
analysi
plaquebas
assay
perform
cell
permit
plaqu
form
quantifi
operatorerror
prone
manual
readout
base
number
plaqu
great
need
novel
technolog
character
dnev
neutral
enhanc
antibodi
simpl
rapid
highthroughput
manner
recent
develop
stabl
luciferas
report
denv
lucdenv
antivir
highthroughput
screen
studi
aim
adapt
lucdenv
antidnev
neutral
enhanc
antibodi
evalu
newli
develop
report
virusbas
assay
valid
use
variou
known
monoclon
antibodi
mab
clinic
sampl
infect
anim
patient
demonstr
well
correl
tradit
plaquebas
assay
lucdenv
develop
engin
renilla
luciferas
gene
capsidcod
region
revers
genet
technolog
shown
lucdenv
replic
effici
mammalian
mosquito
cell
high
stabil
shown
addit
file
figur
addit
file
figur
increas
amount
luciferas
signal
observ
h
postinfect
lucdenv
infect
cell
adapt
lucdenv
neutral
assay
firstli
assay
three
identifi
neutral
mab
use
plaquebas
lucbas
assay
respect
standard
prnt
perform
plate
use
dilut
mab
result
show
three
mab
significantli
reduc
number
plaqu
dosedepend
manner
figur
abc
right
ordin
respect
rlu
base
assay
perform
plate
use
dilut
mab
result
demonstr
three
mab
significantli
decreas
rlu
dosedepend
manner
figur
abc
left
ordin
three
mab
calcul
fit
curv
respect
order
magnitud
unrel
mab
show
neutral
plaqu
lucbas
assay
data
shown
data
fit
made
valu
expect
linear
correl
r
demonstr
pfu
rlu
assay
linear
equat
rlu
pfu
calcul
rlu
pfu
figur
result
support
applic
lucbas
assay
neutral
antibodi
denv
develop
lucdenv
ade
assay
cell
infect
lucdenv
presenc
serial
dilut
viral
titer
supernat
measur
standard
plaquebas
assay
rlubas
assay
respect
result
show
viral
yield
markedli
enhanc
presenc
dilut
rang
peak
enhanc
concentr
figur
right
ordin
rlu
assay
show
similar
pattern
enhanc
peak
enhanc
concentr
figur
left
ordin
similar
magnitud
plaqu
base
assay
get
linear
equat
rlu
pfu
result
obtain
plot
scatter
graph
figur
expect
enhanc
antibodi
titer
determin
rlu
linear
correl
pfu
r
linear
equat
rlu
pfu
obtain
rlu
similar
neutral
equat
togeth
result
indic
novel
report
system
use
lucdenv
readili
antibodi
neutral
enhanc
assay
equival
reliabl
convent
pfubas
assay
final
rlu
base
assay
valid
clinic
sampl
immun
monkey
patient
neutral
assay
perform
use
serial
dilut
sera
cell
enhanc
assay
sera
serial
dilut
assay
perform
cell
sera
rhesu
monkey
immun
live
attenu
show
strong
neutral
activ
calcul
respect
figur
neg
control
ns
healthi
monkey
show
neutral
activ
expect
lucbas
enhanc
assay
show
sera
immun
monkey
could
significantli
enhanc
lucdenv
replic
dilut
respect
enhanc
activ
higher
enhanc
observ
ns
expect
figur
three
convalesc
sera
df
patient
valid
newli
develop
assay
cell
shown
figur
three
sampl
abl
enhanc
denv
infect
dilut
respect
neg
control
nc
healthi
adult
vari
dilut
show
impact
rlu
expect
meanwhil
serum
show
strong
neutral
activ
dilut
even
lower
calcul
dilut
separ
wherea
neutral
activ
observ
serum
detect
dilut
togeth
result
indic
lucbas
assay
suitabl
detect
neutral
ade
activ
immun
sera
vaccin
infect
individu
reliabl
rapid
highthroughput
assay
denv
neutral
antibodi
critic
laboratori
clinic
studi
denv
infect
vaccin
consid
limit
plaqu
base
assay
novel
method
neutral
assay
describ
che
cowork
recent
develop
novel
elispot
base
neutral
test
demonstr
well
correl
convent
prnt
assay
pseudo
infecti
denv
report
viru
particl
rvp
carri
green
fluoresc
protein
gfp
report
also
use
measur
neutral
antibodi
rapid
stabil
reproduc
infect
rvp
could
monitor
gfp
signal
use
flow
cytometri
howev
gfp
suitabl
realtim
quantif
product
rvp
requir
special
cell
line
replicon
base
plasmid
live
report
viru
carri
luciferas
report
replic
almost
wild
type
viru
repres
advanc
tool
mani
report
virus
includ
sarsrel
corona
viru
human
hepat
c
viru
parainfluenza
viru
hiv
adenoviru
describ
well
appli
antivir
screen
live
imag
function
studi
live
report
denv
engin
report
gene
capsid
gene
develop
recent
describ
stabl
luciferas
denv
report
viru
lucdenv
use
highthroughput
screen
antivir
drug
studi
demonstr
util
lucdenv
measur
neutral
enhanc
antibodi
use
three
identifi
neutral
mab
lucbas
assay
show
well
correl
prntbase
assay
isotyp
mab
belong
isotyp
recogn
domain
iii
denv
e
protein
inhibit
viral
bind
inhibit
fusion
three
mab
activ
inhibit
plaqu
form
luc
express
lucdnev
infect
vero
cell
valu
well
correl
r
lucbas
assay
readili
appli
evalu
clinic
sampl
vaccin
anim
infect
patient
ade
infect
denv
well
demonstr
vitro
vivo
repres
one
major
impedi
vaccin
develop
previous
differ
method
base
infect
rate
progeni
viral
yield
number
infecti
center
report
measur
ade
activ
fcr
express
cell
includ
cell
fac
analysi
commonli
use
quantifi
infect
rate
cell
raji
b
human
peripher
blood
mononuclear
cell
progeni
viral
yield
detect
either
convent
plaqu
assay
elisa
elispot
realtim
rtpcr
recent
moi
et
al
success
establish
stabl
cell
line
express
fcriia
facilit
neutral
ade
assay
plaqu
base
assay
determin
infecti
particl
releas
virusinfect
cell
wherea
rlu
base
assay
describ
studi
offer
simpl
method
detect
viral
protein
express
cell
linear
correl
establish
two
assay
neutral
ade
assay
figur
figur
newli
develop
assay
method
compar
tradit
plaqu
assay
uniqu
advantag
first
lucbas
assay
substanti
time
save
convent
plaqu
test
use
plate
day
observ
plaqu
form
new
test
compar
perform
protocol
involv
plate
cost
day
second
new
assay
method
widerang
scope
applic
high
repetit
reliabl
lucdenv
replic
well
multipl
cell
includ
vero
cell
luciferas
activ
also
detect
stabli
variou
cell
neutral
ade
assay
perform
cell
third
new
assay
method
easi
adapt
highthroughput
manner
critic
import
largescal
clinic
sampl
assay
clinic
trial
dengu
vaccin
togeth
establish
novel
report
system
neutral
enhanc
antibodi
assay
denv
use
engin
denv
stabli
express
renilla
luciferas
newli
develop
assay
describ
rapid
lowcost
timesav
provid
use
tool
basic
research
epidemiolog
investig
babi
hamster
kidney
cell
african
green
monkey
kidney
vero
cell
cultur
dulbecco
modifi
essenti
medium
dmem
invitrogen
supplement
fetal
bovin
serum
fb
hyclon
penicillinstreptomycin
co
human
erythroleukem
cell
maintain
rpmi
medium
invitrogen
supplement
fb
gibco
co
report
lucdenv
previous
describ
prepar
titter
vero
cell
follow
character
monoclon
antibodi
mab
denv
use
studi
serum
sampl
collect
rhesu
monkey
immun
singl
dose
live
attenu
denv
unpublish
data
serum
unimmun
anim
set
neg
control
ns
human
convalesc
sera
df
patient
control
serum
neg
denv
nc
guangzhou
peopl
hospit
guangzhou
china
sampl
inactiv
min
assay
prnt
perform
previous
describ
briefli
cellswel
cell
seed
plate
incub
overnight
serial
dilut
antibodi
sampl
mix
equal
volum
lucdenv
contain
pfu
h
incub
antibodyviru
mixtur
ad
cell
monolay
plate
anoth
h
next
supernat
remov
cell
overlaid
ml
wv
agaros
promega
dmem
contain
fb
incub
day
overlay
remov
cell
fix
formaldehyd
min
stain
wv
crystal
violet
dmem
serv
neg
control
sampl
assay
triplic
plaqu
count
defin
antibodi
dilut
result
plaqu
reduct
refer
neg
control
lucbas
neutral
assay
perform
plate
procedur
similar
convent
prnt
assay
briefli
virusantibodi
mixtur
ad
cell
plate
adsorb
h
supernat
remov
ml
fb
replenish
onto
cell
h
incub
supernat
remov
cell
lyse
lysat
promega
per
well
minut
lyse
suspens
assay
enzym
activ
ad
substrat
reagent
data
collect
use
continuousread
luminomet
glomax
micropl
luminomet
promega
integr
second
second
delay
medium
serv
neg
control
sampl
assay
triplic
antibodi
dilut
result
reduct
rlu
valu
refer
neg
control
defin
protocol
ade
assay
previous
describ
briefli
preform
antibodydnev
complex
prepar
incub
serial
dilut
antibodi
lucdenv
moi
appli
cell
plate
cell
incub
addit
hour
viru
titer
supernat
titrat
standard
plaqu
assay
cell
lucbas
ade
assay
oper
similar
plaquebas
enhanc
assay
describ
plate
serial
dilut
antibodi
mix
lucdenv
incub
hour
cell
cell
lysat
subject
luciferas
activ
assay
describ
enhanc
activ
evalu
compar
rlu
valu
cell
harbor
antibodylucdenv
complex
cell
harbor
lucdenv
alon
statist
analys
perform
use
spss
graph
perform
use
prism
softwar
san
diego
ca
data
present
mean
plu
standard
deviat
independ
experi
p
valu
consid
statist
signific
